18 August 2016: Link here. Rex Bionics Plc (AIM: RXB), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, is pleased to announce positive results from a second interim analysis of its RAPPER II clinical trial. RAPPER II is multi-centre, international trial to evaluate the feasibility and safety of the […]
Melbourne, Australia, 16th August 2016 Link here.
05 August 2016: Rex Bionics plc (AIM: RXB), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, is today pleased to announce that Maxhealth Medicine Co. Ltd has now deposited £1 million in escrow in relation to its subscription for 3,333,333 ordinary shares at 30p each. This £1 million will […]
Melbourne, Australia, 4 August 2016: Link here. Adherium has appointed its new Chief Operating Officer, Ross Bradding, and a new Head of Corporate Development, Julia Chambers.
Wednesday, August 3, 2016 8:45 am EDT SAN DIEGO–(BUSINESS WIRE)–Link here. AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced it has completed enrollment of its Phase 1 clinical trial to evaluate the safety of AB-SA01, its proprietary phage cocktail targeting Staphylococcus aureus (S. […]
DUBLIN, Ireland, July 20, 2016 (GLOBE NEWSWIRE) –Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapeutics company, today announced the recent publication of two peer-reviewed papers regarding frunevetmab in the Journal of Veterinary Internal Medicine (JVIM), as well as an upcoming presentation by Nexvet’s Chief Scientific Officer Dr. David Gearing at the Veterinary Pain Short […]
NZX / MEDIA RELEASE 18 July 2016. Link here. SeaDragon appoints new Chief Executive Dr Nevin Amos to take the reins of the company in October 2016. SeaDragon Board thanks outgoing Interim Chief Executive Richard Alderton for leadership through the company’s transition to Omega-3 fish oil markets SeaDragon, New Zealand’s largest refiner and blender of […]
Biomedicine: Move over, morphine James Mitchell Crow Nature 535, S4–S6 (14 July 2016) Published online 13 July 2016 Link here.
Northridge, CA, Perth, Australia and London, United Kingdom – 11 July 2016 Avita Medical Ltd today announced a partially underwritten non-renounceable rights issue to raise up to approximately $11m (Rights Issue) to support the Company’s strategy to launch in the US and push forward with product commercialization. Link here.
Northridge, CA, Perth, Australia and London, United Kingdom – 29 June 2016 Link here.